Fjarde AP-fonden
VC Fund
Stockholm, Sweden
Fjarde AP-fonden is a VC fund in Stockholm focused on Biotechnology and Real Estate. Fourth AP Fund is an investment management company.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Fjarde AP-fonden invests in
Stages Fjarde AP-fonden invests in
Countries Fjarde AP-fonden invests in
Investment Focus
Industry
- Biotechnology 3 (33%)
- Real Estate 2 (22%)
- Pharmaceutical 2 (22%)
- Retail 1 (11%)
- Biopharma 1 (11%)
Stage
- Post-IPO Equity 4 (44%)
- Private Equity 1 (11%)
- Venture - Series Unknown 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Swedish Logistic Property (SLP) specializes in the development and management of logistics properties across Sweden. With a focus on energy efficiency, SLP provides modern logistics solutions tailored to meet the needs of various businesses. The company's portfolio includes strategically located properties designed to support efficientlogistics and supply chain operations. SLP also engages in the acquisition and development of new properties, aiming to expand its footprint in the logistics real estate market. The company's commitment to sustainability is evident in its construction practices and the operation of its logistics facilities. | $85.3M / Post-IPO Equity / Dec 03, 2025 | |
|
|
Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal. | $48M / Post-IPO Equity / Nov 13, 2025 | |
|
|
Stendorren Fastigheter is a company involved in the real estate industry. It develops, owns, operates, and maintains industrial, logistical, and warehouse facilities. The business offers adequate and suitable space on fair lease terms through its tenant. | $47.7M / Post-IPO Equity / Oct 23, 2024 | |
|
|
ITAB Shop Concept sells, develops, manufactures and installs complete shop fitting concepts for retail chain stores. The company offers custom-made fitting concepts, innovative solutions for checkout arena and professional lighting systems. | $85.1M / Post-IPO Equity / Sep 25, 2024 | |
|
|
Swedish Logistic Property (SLP) specializes in the development and management of logistics properties across Sweden. With a focus on energy efficiency, SLP provides modern logistics solutions tailored to meet the needs of various businesses. The company's portfolio includes strategically located properties designed to support efficientlogistics and supply chain operations. SLP also engages in the acquisition and development of new properties, aiming to expand its footprint in the logistics real estate market. The company's commitment to sustainability is evident in its construction practices and the operation of its logistics facilities. | $107.1M / Post-IPO Equity / Sep 04, 2024 | |
|
|
SmartCella is an innovative biotechnology and medtech company. Sweden. SmartCella’s therapeutic mission is to develop treatments for patients running out of options. The company has three main business units, Procella Therapeutics, Smartwise and SvedMed Solutions. | $54.2M / Private Equity / Jul 08, 2024 | |
|
|
Swedish Logistic Property (SLP) specializes in the development and management of logistics properties across Sweden. With a focus on energy efficiency, SLP provides modern logistics solutions tailored to meet the needs of various businesses. The company's portfolio includes strategically located properties designed to support efficientlogistics and supply chain operations. SLP also engages in the acquisition and development of new properties, aiming to expand its footprint in the logistics real estate market. The company's commitment to sustainability is evident in its construction practices and the operation of its logistics facilities. | $53.1M / Post-IPO Equity / Nov 29, 2023 | |
|
|
Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal. | $46.2M / Post-IPO Equity / Jun 09, 2023 | |
|
|
Cinclus Pharma AG is a research based biotech company developing small molecules for the treatment of gastric acid related diseases. Their main asset, X842, has been studied in a Phase I clinical trial. Cinclus Pharma is based in Basel, Switzerland. | $24.1M / Venture - Series Unknown / May 20, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Fjarde AP-fonden invest in?
Fjarde AP-fonden invests primarily in Biotechnology, Real Estate and Pharmaceutical startups, most often at Post-IPO Equity and Private Equity stage. Most of the 9 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Fjarde AP-fonden last invest?
The most recent investment recorded for Fjarde AP-fonden closed in Dec 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!